Quantification of GPC1(+) Exosomes Based on MALDI-TOF MS In Situ Signal Amplification for Pancreatic Cancer Discrimination and Evaluation
Analytical Chemistry · 2023
DOI: 10.1021/acs.analchem.3c00193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2023. Verfasst von Shaohan Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Institutes of Biomedical Sciences, Fudan University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Exosomes, Metal Nanoparticles, Pancreatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pancreatic cancer (PC) has a high mortality, with a fairly low five-year survival rate, because of its delayed diagnosis. Recently, liquid biopsy, especially based on exosomes, has attracted vast attention, thanks to its low invasiveness. Herein, we constructed a protocol for pancreatic cancer related Glypican 1 (GPC1) exosome quantification, based on in situ mass spectrometry signal amplification, by utilizing mass tag molecules on gold nanoparticles (AuNPs). Exosomes were extracted and purified by size-exclusion chromatography (SEC), captured by TiO2 modified magnetic nanoparticles, and then targeted specifically by anti-GPC1 antibody modified on AuNPs. With matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), the signal of PC biomarker, GPC1, was converted to a mass tag signal and amplified. With addition of a certain amount of internal standard molecules modified on AuNPs, the relative intensity ratio of mass tag to internal standard was proportional to the concentration of GPC1(+) exosomes derived from pancreatic cancer cell lines, PANC-1, with good linearity (R2 = 0.9945) in a wide dynamic range from 7.1 × 10 to 7.1 × 106 particles/μL. This method was further applied to plasma samples from healthy control (HC) and pancreatic cancer patients with different tumor load, and exhibited a great potential in discriminating diagnosed PC patients from HC, and has the monitoring potential in PC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Institutes of Biomedical Sciences, Fudan University, Shanghai 200433, China.
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
ORCID-Profile: Mingxia Gao, Xiangmin Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yan, S., Zheng, H., Zhao, J., Gao, M., & Zhang, X. (2023). Quantification of GPC1(+) Exosomes Based on MALDI-TOF MS In Situ Signal Amplification for Pancreatic Cancer Discrimination and Evaluation. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.3c00193
Vancouver
Yan S, Zheng H, Zhao J, Gao M, Zhang X. Quantification of GPC1(+) Exosomes Based on MALDI-TOF MS In Situ Signal Amplification for Pancreatic Cancer Discrimination and Evaluation. Analytical Chemistry. 2023. doi:10.1021/acs.analchem.3c00193
BibTeX
@article{Yan2023,
author = {Yan, Shaohan and Zheng, Haoyang and Zhao, Jiandong and Gao, Mingxia and Zhang, Xiangmin},
title = {Quantification of GPC1(+) Exosomes Based on MALDI-TOF MS In Situ Signal Amplification for Pancreatic Cancer Discrimination and Evaluation},
journal = {Analytical Chemistry},
year = {2023},
doi = {10.1021/acs.analchem.3c00193}
}
EUVIMED